Satellite Symposia

Hear directly from industry in these popular one-hour presentations. Check back as details are added frequently.
Note: CE Credits not offered for Satellite Symposia unless otherwise specifically noted.

Sunday, June 25

6:45–7:45 am CT 

Navigating the New Era of Molecularly-Defined Care in Alzheimer's Disease: Applying Nuclear Medicine to Quantify Neuropathology and Improve Diagnostic Accuracy in the Earliest Stages of the AD Continuum
(CME-Certified Symposium)


  • Co-Chair & Presenter: Gil Rabinovici, MD; Edward Fein & Pearl Landrith Distinguished Professor; Director, UCSF Alzheimer’s Disease Research Center Departments of Neurology, Radiology and Biomedical Imaging; University of California, San Francisco; San Francisco, California
  • Co-Chair & Presenter: Ilya M. Nasrallah, MD, PhD; Department of Radiology; University of Pennsylvania; Philadelphia, Pennsylvania

Significant advances have been made in the development and validation of molecular imaging tools and quantitation techniques that may aid in the detection and diagnosis of Alzheimer’s disease (AD). Join PeerView for this educational symposium, where a panel of AD experts will illustrate how to integrate validated and emerging PET radiotracers and quantitative measures into clinical practice. Through a case-based discussion, this interactive symposium will offer learners an in-depth look at the complex diagnostic challenges associated with mild cognitive impairment and early AD dementia, and will provide practical guidance on effectively and appropriately incorporating amyloid PET, FDG PET, and tau PET imaging into patient care to facilitate timely and accurate AD diagnosis. Attendees will also learn about quantitation tools that can improve the diagnostic accuracy, sensitivity, and specificity of PET image interpretation.

For more information, please visit:

This CME activity is provided by PVI, PeerView Institute for Medical Education.
This activity is supported by an educational grant from Lilly.

6:45–7:45 am CT

Unleashing the Power of Total-Body PET/CT: Reflections on 5 Years of Progress 


  • Dr. Ramsey Badawi,Vice-Chair for Research, Department of Radiology, UC Davis
  • Dr. Hongcheng Shi, Director, Department of Nuclear Medicine, Zhongshan Hospital of Fudan University
  • Dr. Harshad Kulkarni, Chief Medical Advisor, BAMF Health
  • Dr. Zhi Yang,Director, Department of Nuclear Medicine, Peking Cancer Hospital

Witness the Extraordinary Capabilities of uEXPLORER®: The World's First and Only 2 m Total-Body PET/CT Scanner.  Join us for an enlightening session as we explore a captivating showcase of the latest breakthroughs in clinical and research domains.

11:15 am–12:15 pm CT

PSMA PET: Imaging Engineered

This presentation will discuss the most recent innovation in PSMA-PET imaging for prostate cancer.

11:15 am–12:15 pm CT


PSMA PET Imaging: Five Years of Experience from Research to Clinical Use

Andrei Iagaru, MD, Professor of Radiology - Nuclear Medicine and Chief, Division of Nuclear Medicine and Molecular Imaging at
Stanford University

PSMA PET changed the way that patients with prostate cancer are managed from initial treatment to biochemical recurrence. Here we will review data from the research use to clinical implementation, as well as new emerging uses and the introduction of artificial intelligence for scan interpretation and reporting.

11:15 am–12:15 pm CT


Utilizing Imaging to Identify Patients with Transthyretin Amyloid Cardiomyopathy (ATTR-CM) for Appropriate Diagnosis and Treatment

Saurabh Malhotra, MD, MPH, FACC, FASNC, Director of Advanced Cardiac Imaging and Amyloidosis Program, Associate Professor of Medicine, Cook County Health, Chicago, IL

Transthyretin amyloid cardiomyopathy (or ATTR-CM) is a serious underrecognized and underdiagnosed disease that frequently presents as heart failure. Join us to help raise awareness of the signs and symptoms of ATTR-CM, and the role of cardiac health professionals in suspecting, diagnosing, and confirming ATTR-CM. This presentation will introduce approaches to achieve a diagnosis—with a focus on nuclear scintigraphy and include a review of the clinical data for a treatment option for ATTR-CM. 


6:30–7:30 pm CT


Timely Alzheimer's Disease Diagnosis for
Clinical Management: The Integrated Role of PET Imaging


  • Giuseppe Esposito, MD, Chief of Nuclear Medicine & PET/CT, Professor of Radiology, MedStar Georgetown University Hospital, Washington, DC, USA
  • R Scott Turner, MD, PhD, Director, Memory Disorders Program, Professor, Dept of Neurology, Georgetown University Medical Center, Washington, DC, USA
Please join us as two clinical experts in the fields of Neurology and Nuclear Medicine discuss the role of PET imaging in the diagnosis and management of mild cognitive impairment (MCI) and dementia associated with Alzheimer’s disease (AD).  The speakers will provide insights on topics including:  the key features and imaging scenarios encountered in MCI and AD dementia, interpreting scans for amyloid deposition, comparing the various amyloid PET ligands, the role of amyloid PET imaging in AD diagnosis, optimizing the communication of imaging discussions with the multi-disciplinary team, and learnings from the original and ongoing Imaging Dementia—Evidence for Amyloid Scanning (IDEAS) studies and New IDEAS studies. The session will highlight the perspective of a collaborative clinical team and how imaging can be incorporated into the management and decision-making of patients with suspected AD. This session, which will include dialogue between the experts and practical illustrative case studies, aims to provide information to healthcare professionals that may be helpful for improving the diagnosis and clinical management of AD. 

6:30–7:30 pm CT


Investing Into the Future of Theranostics: Aligning Supply to the Clinical Needs


  • Dr. Harshad Kulkarni, BAMF Health - Current and future utilization of Theranostics: A clinical perspective
  • Neil Quigley, M.Sc. - Synergy between Lu-177 & Ac-225: A radiochemistry perspective  
  • Ram Mullur, M.Sc., MBA VP-Canadian National Laboratories - Commercial Availability of Ac-225: A Technology perspective

 session examines the current landscape and promising future of theranostics, from three distinct but equally important vantage points: The clinician, the radiochemist, and the manufacturer.   Understanding the interdependency of these stakeholders will help ensure the value of this critical modality for patients now and well into the future.  

6:30–8:30 pm CT
Sponsored by: SOFIE

FAP Ligands for Imaging and Therapy

Frederik L. Giesel, MD, MBA, University Hospital Düsseldorf

Olivia Newton-John Cancer Research Institute                                        

Rodney Hicks, MBBS (Hons), MD, FRACP, FICIS, FAAHMS
Melbourne Theranostic Innovation Center

Current State of FAP Imaging
Ajit Goenka, MD, Mayo Clinic
Elcin Zan, MD, Cornell University
Ali Pirasteh, MD, UW Madison
Frank Bengel, MD, Medical School Hannover

Current State of FAP Therapeutics
Wolfgang P. Fendler, MD, Essen University Hospital
Mark Sellmyer, MD, PhD, University of Pennsylvania
Delphine Chen, MD, University of Washington

Clinical Development/Industry Updates
Sherly Mosessian, PhD, SOFIE
Jacqueline Mock, PhD, Philochem, Philogen
Amanda Walker, MD, POINT Biopharma
Xiaoyuan (Shawn) Chen, PhD, National University of Singapore

Panel Discussion – moderated by Frederik L. Giesel, MD, MBA 
Tadashi Watabe, MD, PhD, FANMB, Osaka University
Vasko Kramer, PhD, Positronpharma SA
Haojun (Leo) Chen, MD, First Affiliated Hospital of Xiamen University
Jeremie Calais, MD, Msc, University of California, Los Angeles

FAP (fibroblast activation protein) as a diagnostic and therapeutic target for radiopharmaceuticals has seen many advances in recent years. This special session will bring together researchers and industry sponsors to discuss the latest progress in this space.

Flyers: SOFIE, Philogen/Philochem, and Yantai

Monday, June 26

6:45–7:45 am CT

Delivering High-dose Targeted Radiotherapy with Safety and Tolerability of Reduced
Intensity Conditioning with lomab-B (I131-apamistamab) in the SIERRA Study: the Nuclear Medicine Perspective 


  • Neeta Pandit-Taskar, MD; Clinical Director, Radioimmunotherapy & Theranostics Ludwig Center Cancer Immunotherapy, MSKCC; Professor of Radiology, Weill Cornell Medical College
  • Akash Nahar, MD; Vice President, Clinical Development, Actinium Pharmaceuticals
  • Madhuri Vusirikala, MD; Vice President, Clinical Development BMT and Cellular Therapy, Actinium Pharmaceuticals


  • Patrik Brodin, PhD, DABR; Vice President, Head of Radiation Sciences, Actinium Pharmaceuticals


  • The recently completed Phase 3 SIERRA trial showed the impact of Iomab-B as a myeloablative regimen for patients with relapsed/refractory AML prior to an allogenic stem cell transplant
  • Personalized doses using high levels of I-131 activity were delivered by nuclear medicine teams in a multitude of participating centers across the United States and Canada
  • Data on the outcome of this trial will be presented, with a focus on the nuclear medicine experience and how this therapy was delivered safely and securely in a variety of clinical settings

6:45–7:45 am CT

Building Your Future in Theranostics


  • Dr. Delphine L. Chen, MD, Director of Molecular Imaging, Fred Hutchinson Cancer Center
    • Establishing and Expanding a Theranostics Center of Excellence
  • Dr. Brandon Mancini, MD, MBA, FACRO, Medical Director at BAMF Health
    • Scalability of Theranostics department design and collaborative partnerships

Theranostics is enabling solutions for a new era in cancer care. This symposium will explore how two thought leaders in Molecular Imaging and Radiation Oncology are helping their practice navigate the growing patient demand for Theranostics by sharing their unique experiences and perspectives.

6:45 am–7:45 am CT


PSMA PET in Prostate Cancer: A Case-Based Discussion


  • Jason Efstathiou, MD, DPhil, FASTRO, FACRO, Professor of Radiation Oncology, Harvard Medical School, Director, Genitourinary Service, Department of Radiation Oncology, Clinical Co-Director, The Claire and John Bertucci Center for Genitourinary Cancers, Massachusetts General Hospital, Boston, MA
  • Leonard (Lenny) Gomella, MD, FACS, Thomas Jefferson University Hospital, Philadelphia, PA
  • Michael A. Gorin, MD, Associate Professor of Urology, Icahn School of Medicine at Mount Sinai, New York, NY
  • Phillip Koo, MD, Chief Diagnostics Imaging and Oncology Physician Executive, Banner MD Anderson Cancer Center, Gilbert, AZ
  • Oliver Sartor, MD, Professor of Medicine, Urology, and Radiology, Director of Radiopharmaceutical Trials, Mayo Clinic, Rochester, MN

In this session the expert panel will highlight real-world patient cases that support the use of PSMA PET/CT in the treatment of prostate cancer, following NCCN Guidelines:

  • Initial staging workup for unfavorable intermediate-risk, high-risk, and very high-risk local or newly diagnosed prostate cancer
  • PSA persistence or recurrence after radical prostatectomy or radiotherapy
  • Progressing CRPC
  • Selection of Patients for radioligands therapy

The session will also explore ways to maximize multidisciplinary collaboration in the utilization of PSMA PET/CT imaging. The session will conclude with a Q&A.

11:30 am–12:30 pm CT


Unlocking the New Era in Nuclear Pulmonology 


  • Professor Dale Bailey PhD FIPEM FACPSEM MRCP(Lond.) CSci (UK), Principal Medical Physics Specialist, Department of Nuclear Medicine, Royal North Shore Hospital
  • Professor Pierre-Yves SALAÜN, MD-PhD, Chef de Service, Service de Médecine Nucléaire, CHRU de BREST
  • Dr. Sarah Svenningsen, Assistant Professor of Medicine, McMaster University, Firestone Institute for Respiratory Health & Imaging Research Centre, St. Joseph's Healthcare Hamilton
  • Mr. James McBrayer, Cyclomedica Managing Director and CEO, Sydney , Australia
We are Cyclomedica – bringing light into Molecular Imaging. Come join us at our luncheon symposium during the SNMMI 2023. From innovation, development to clinical practice applications – we are the world leaders in functional lung ventilation imaging with our proprietary technology:  Technegas®. A new era in Nuclear Pulmonology continues to unlock as new innovations come to light. Come and explore Technegas® in your department, the current clinical applications and several potential new Beyond PE indications for functional lung imaging. Hear about our ongoing research around the globe,  our pathway and USFDA update.

11:30 am–12:30 pm CT

Expanding Access to Care with Modern
Molecular Imaging

  • Integrating theranostics to extend care to more patients
  • Leveraging high-performance SPECT/CT to move nuclear medicine to the next level

This two-part symposium will showcase how one U.S. hospital is leveraging its theranostics program to provide personalized cancer care for a diverse patient population. Learn about the center’s clinical workflow as well as its routine utilization of PET/CT and SPECT/CT imaging.

Expanding access to next-generation theranostics

  • SpeakerJoseph R. Osborne, MD, PhD; Chief, Division of Molecular Imaging and Therapeutics, Professor of Radiology, Weill Cornell Medicine, New York, New York
A second presentation will highlight how workflow efficiencies and enhanced imaging capabilities gained from upgrading older SPECT/CT technology have impacted a department’s capacity to consistently deliver a high-quality imaging experience for patients, referring physicians, and staff.

Symbia Pro.specta: Putting the 'Pro' in SPECT/CT Imaging

  • Speakers: Alex Torres, CNMT, (ARRT) (N)(CT) and Natasha Befrui B.S., CNMT, (ARRT)(N)(CT); Nuclear Medicine Technologists, Department of Radiology Houston Methodist Hospital, Houston, Texas

Symbia Prospecta is not available in all countries. Its future availability cannot be guaranteed.

11:30 am–12:30 pm CT


Advancing Precision Medicine: Unprecedented PET/CT Technology for Clinical Molecular Imaging


  • Dr. Jeffrey Yap, Director, Center for Quantitative Cancer Imaging at Huntsman Cancer Institute
  • Dr. Li Huo, Director, Department of Nuclear Medicine, Peking Union Medical College Hospital

Embark on a transformative journey and witness the groundbreaking impact of uMI Panorama on global clinical molecular imaging. Join renowned speakers as we delve into cutting-edge advancements and inspiring success stories that redefine the future of precision medicine through Molecular Imaging.

5:45 –6:45 pm CT


The Past, Present and Future of Xofigo: The First and Only Alpha Targeted Therapy For Advanced Prostate Cancer


  • Dr. Neal Shore, Medical Director, Caroline Urologic Research Center, Chief Medical Office, GenesisCare, US Surgery and Urology, South Carolina
  • Dr. Shawn H. Zimberg, MD, National Director of Radiation Oncology, Solaris Health Partners, Medical Director, Advanced Radiation Centers of New York

1 hour educational session on how best to identify and sequence metastatic prostate cancer patients on Xofigo. The session will cover key clinical trial and latest Real world evidence data. Session experts will also provide HCP insights on how can one extend Xofigo’s benefit to all eligible patients.

Tuesday, June 27

12:00 pm–1:00 pm CT 

Patient Care with Total-body PET/CT  

Speakers from prominent U.S. hospitals will provide insight into the core characteristics of modern PET/CT plus share how total-body PET/CT imaging with Biograph Vision Quadra™ is advancing their clinical and research programs.


  • Geoffrey B. Johnson, MD, PhD; Department of Radiology, Nuclear Medicine, Mayo Clinic, Rochester, Minnesota
  • Osama R. Mawlawi, PhD; Professor of Imaging Physics and Section Chief of Nuclear Medicine Physics, University of Texas, MD Anderson Cancer Center, Houston, Texas

Biograph Vision Quadra is not available in all countries. Its future availability cannot be guaranteed.

12:00 pm–1:00 pm CT 

Spectrum Dynamics Medical:  Reaching Higher Peaks in Digital SPECT Imaging


Dr. Matthew Robertson, Instructor in Radiology Brigham and Women's Hospital, Massachusetts USA

  • 4D Hepatobiliary Scintigraphy. Dynamic SPECT/CT clinical implementation and problem solving 

Dr. Benjamin Auer, Director of Nuclear Medicine Physics at Brigham and Women's Hospital, Massachusetts USA

  • Quantitative 360-degree CZT SPECT/CT Imaging: The Brigham and Women’s Hospital Experience

Dr. Babak Saboury, Chief Clinical Data Science Officer at The National Institutes of Health, DC USA

  • Not just more detectors around: Indispensable role of higher-energy detectors in performance of novel geometry SPECT camera for precision radiopharmaceutical therapy of tomorrow (Case Study of VERITON 400)

Dr. Sanjay Divakaran, Associate Director Nuclear Cardiology Brigham and Woman’s Hospital, Massachusetts USA

  • Clinical and operational aspects of TruCorr